HC Wainwright Reaffirms Buy Rating for Repare Therapeutics (NASDAQ:RPTX)

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $10.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 202.11% from the company’s current price.

Separately, Lifesci Capital raised shares of Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th.

Repare Therapeutics Stock Performance

Shares of NASDAQ:RPTX traded down $0.12 during trading on Thursday, hitting $3.31. The company’s stock had a trading volume of 29,204 shares, compared to its average volume of 166,686. The company has a market capitalization of $140.51 million, a PE ratio of -2.02 and a beta of 0.72. Repare Therapeutics has a fifty-two week low of $2.71 and a fifty-two week high of $8.49. The stock’s 50-day moving average price is $3.21 and its two-hundred day moving average price is $3.39.

Repare Therapeutics (NASDAQ:RPTX) last released its earnings results on Tuesday, August 6th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.03. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 31.11%. The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $4.02 million. On average, equities analysts predict that Repare Therapeutics will post -2.15 earnings per share for the current fiscal year.

Institutional Trading of Repare Therapeutics

Several hedge funds have recently added to or reduced their stakes in RPTX. Vontobel Holding Ltd. grew its stake in shares of Repare Therapeutics by 20.0% in the third quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares in the last quarter. XTX Topco Ltd acquired a new stake in Repare Therapeutics in the second quarter worth about $110,000. Exchange Traded Concepts LLC grew its position in Repare Therapeutics by 21.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock valued at $174,000 after buying an additional 8,809 shares in the last quarter. Marshall Wace LLP acquired a new position in Repare Therapeutics during the 2nd quarter valued at about $273,000. Finally, Opaleye Management Inc. bought a new stake in shares of Repare Therapeutics during the 1st quarter worth about $318,000. Institutional investors own 85.09% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.